NỒNG ĐỘ IL-6 HUYẾT THANH THEO PHÂN NHÓM BMI VÀ ALT HUYẾT TƯƠNG Ở NGƯỜI MẮC BỆNH GAN NHIỄM MỠ KHÔNG DO RƯỢU

Abstract

Introduction: Elevated Interleukin-6 (IL-6) levels in patients with non-alcoholic fatty liver disease (NAFLD) may originate from hepatic inflammation, suggesting the potential of IL-6 as a biomarker to support the diagnosis of non-alcoholic hepatitis. Objectives: To determine serum IL-6 levels in individuals with NAFLD and compare the differences in serum IL-6 levels according to BMI groups and ALT levels in this population. Subjects and Methods: A cross-sectional study was conducted on 144 patients diagnosed with fatty liver through abdominal ultrasound at Nguyen Tri Phuong Hospital from March to June 2023. Serum IL-6 and ALT levels were measured at the hospital's laboratory. Data was analyzed using Stata 14.0 software. The Mann-Whitney and Kruskal-Wallis tests were used to assess differences with significance at p < 0.05, and Spearman correlation was used to evaluate the correlation. Results: The median serum IL-6 level in the study population was 51.08 pg/mL (30.82 – 87.17). There were no statistically significant differences in serum IL-6 levels according to BMI and ALT groups. There was a moderate and statistically significant positive correlation (r = 0.33, p = 0.012) between serum IL-6 levels and BMI in the obese NAFLD group. Conclusion: Serum IL-6 levels were determined in the study subjects. Preliminary findings indicated a correlation between serum IL-6 levels and BMI in the obese NAFLD group.